Nycomed (Hong Kong) Limited是一家香港公司,现已更名为武田药品(香港)有限公司,该页面展示了武田药品(香港)有限公司的中文名称、英文名称、注册编号、商业登记号、成立日期、改名日期、公司状态、变更历史等信息,提供Nycomed (Hong Kong) Limited详情企业报告定购服务。 已经成立了13年11个月14天。 Ny
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Takeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.
Statements | Takeda PharmaceuticalsStatements# StatementsLocations Contact us Careers Financial Highlights HCPs Patients This website provides information about Takeda's worldwide business. For specific information about our local markets, please use the country selector.This website provides information about...
We focus on innovations that contribute to making a difference in people’s lives. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vacci...
This page provides downloadable Takeda Pharmaceuticals charters and reports including our articles of incorporation.
Hong Kong SAR Hungary India Indonesia Ireland Israel Italy J - R Japan Kazakhstan Korea Latvia Lithuania Malaysia Mexico Netherlands New Zealand Norway Peru Philippines Poland Portugal Romania Russia S - V Saudi Arabia Serbia Singapore Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Th...
This will be followed by planned submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) and a JNDA to the Japan Pharmaceuticals and Medical Devices Agency (PMDA). Under the terms of the...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion (KRX:068270) announced today that it has signed an agreement to acquire product assets for the Asia Pacific region from Takeda Pharmaceuticals International AG (“Takeda”) in an effort to strengthen its R&D capabilities in the Global Small Molecule...
Celltrion (KRX:068270) announced today that it has signed an agreement to acquire product assets for the Asia Pacific region from Takeda Pharmaceuticals International AG (“Takeda”) in an effort to strengthen its R&D capabilities in the Global Sma...